Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans.
Chattopadhyay N, Kanacher T, Casjens M, Frechen S, Ligges S, Zimmermann T, Rottmann A, Ploeger B, Höchel J, Schultze-Mosgau MH. Chattopadhyay N, et al. Among authors: ploeger b. Br J Clin Pharmacol. 2018 Dec;84(12):2857-2866. doi: 10.1111/bcp.13750. Epub 2018 Oct 11. Br J Clin Pharmacol. 2018. PMID: 30171692 Free PMC article.
Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure-response modelling and simulation.
Sutter G, Frei M, Schultze-Mosgau MH, Petersdorf K, Seitz C, Ploeger BA. Sutter G, et al. Among authors: ploeger ba. Br J Clin Pharmacol. 2022 Feb;88(2):734-741. doi: 10.1111/bcp.15014. Epub 2021 Aug 25. Br J Clin Pharmacol. 2022. PMID: 34327754 Free PMC article.
Marginal increase of sunitinib exposure by grapefruit juice.
van Erp NP, Baker SD, Zandvliet AS, Ploeger BA, den Hollander M, Chen Z, den Hartigh J, König-Quartel JM, Guchelaar HJ, Gelderblom H. van Erp NP, et al. Cancer Chemother Pharmacol. 2011 Mar;67(3):695-703. doi: 10.1007/s00280-010-1367-0. Epub 2010 May 29. Cancer Chemother Pharmacol. 2011. PMID: 20512335 Free PMC article. Clinical Trial.
Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer.
Grevel J, Jentsch G, Austin R, Prins NH, Lettieri J, Mitchell D, Huang F, Brose MS, Schlumberger M, Meinhardt G, Peña CEA, Ploeger BA. Grevel J, et al. Clin Transl Sci. 2019 Sep;12(5):459-469. doi: 10.1111/cts.12634. Epub 2019 Apr 12. Clin Transl Sci. 2019. PMID: 30920122 Free PMC article. Clinical Trial.
Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.
Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, Garmann D, Ploeger B, Eissing T. Snelder N, et al. Among authors: ploeger b. Clin Pharmacokinet. 2020 Mar;59(3):359-370. doi: 10.1007/s40262-019-00820-x. Clin Pharmacokinet. 2020. PMID: 31583611 Free PMC article. Clinical Trial.
NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure.
Schmitt W, Rühs H, Burghaus R, Diedrich C, Duwal S, Eissing T, Garmann D, Meyer M, Ploeger B, Lippert J. Schmitt W, et al. Among authors: ploeger b. Clin Pharmacol Ther. 2021 Aug;110(2):498-507. doi: 10.1002/cpt.2222. Epub 2021 Mar 27. Clin Pharmacol Ther. 2021. PMID: 33630302 Free PMC article.
65 results